LAS VEGAS, NV--(Marketwire - Jan 7, 2013) - The President

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
LAS VEGAS, NV--(Marketwire - Jan 7, 2013) - The President of Cytta Corp. (OTCBB: CYCA) (OTCQB: CYCA), manufacturer of the CyttaConnect Open Source mobile monitoring technology, has issued the following update outlining the Company's future plans in anticipation of their upcoming licensing meetings at CES this week. Cytta Corp. has successfully completed the design, development and now full scale trial implementation of the world's first open source special purpose cellular network. Cytta Connect's first Trial makes available a plethora of exciting, yet affordable and easy-to-use Bluetooth based medical/health/wellness testing products and services, which connect through our open source smartphones. Our smartphones allow people and their physicians to monitor their personal health, wellness and fitness in addition to all normal smartphone functionality.  Additionally, while we designed our technology for the exceptionally high standards of the medical industry, our open source mobile network is 'any Bluetooth device friendly.' Our network allows us to connect any data generating devices via Bluetooth through our proprietarily programmed smartphones and deliver that data in real time to a web based interface and then back to the smartphone. We formed the Company with the idea of revolutionizing the home based medical testing sector and then we created a new form of mobile network designed to move generated data seamlessly.  We commissioned Connected Health Pte. Ltd., to create a mobile phone based monitoring technology. They developed a proprietary technology utilizing the native programing in our cell phones, which we call the "Super App." This technology allows our cell phones to seamlessly connect with Bluetooth medical and other testing devices and automatically forward that data to our cloud based database and downstream users.  The Super App technology required that we obtain access to a US Mobile Network and obtain authorization to alter native phone programming and create a proprietary special purpose network. We partnered with Vonify Inc. for a full MVNO (Mobile Virtual Network Operator) status and assisted with the integration of the Super App with their US cellular network. Months of arduous testing involving all elements of the solution including voice, data and SMS have resulted in an integrated network capability that exceeds any other alternative. Additionally, we have now secured and fully implemented a US and International Data MVNO from AT&T which provides us with backup and additional network opportunities. Moving medical data that could be directly 'utilized' by medical professionals required the use of high quality FDA approved Bluetooth medical testing devices. We were able to automatically utilize our Super App to integrate into our Bluetooth ecosystem, the A&D Medical scale, the A&D Medical blood pressure device, the Nonin Medical Inc. pulse oximetry device and the "MyGlucoHealth" diabetes meter from Entra Health Systems. However the Cytta Connect network and smartphones can easily interface with any information generating Bluetooth device. We created an internet or Cloud based Electronic Relational Database to act as a Medical Record for the data from our devices to populate, since there was no precedent for the real time medical database the medical devices were now generating. The Cytta Dashboard or Instant EMR is automatically populated with the patient's data and provides an interactive and interpretive interface for review by the patient's providers and caregivers. The data can be displayed in various numerical formats, it can be graphed to show trends of these measurements and it may be utilized to provide early warning signs of dangerous health trends. The Dashboard can also be used to monitor and issue warnings for any type of data being generated. Licensing discussions in the Oil and Gas, Transportation, Security and other industries are ongoing. Having 'premiered' our technology in the medical monitoring industry, we needed a medical technical organization to be responsible for the servicing of the high end medical testing units being deployed in our Field Trial. We worked with Medi-Home Individualized Monitoring Systems Corp. (MHIMS) who helped design the Trial and then implemented the ecosystem of devices to be utilized by the patients to provide meaningful and timely information to their caregivers in real time.  We established our initial Pilot Program installation with the Heritage Provider Network (HPN) Regal /Lakeside Medical Group, under the auspices of Dr. Terry Olson. HPN is a large full risk, capitated medical group located in Southern California. Under the terms of the Trial they completed a 90 day and more recently a 120 day Pilot Study to determine, 'if high cost patients, not well managed in traditional care coordination programs and traditional healthcare delivery systems, can decrease cost of care and improve patient satisfaction, through remote telemonitoring using the CYTTA Connect Ecosystem and an intense case management process.' Patient satisfaction and costs reductions were then measured. MHIMS provided assistance and advice in conjunction with Dr. Terry Olson's team. Cytta is delighted with the results MHIMS and Dr. Olson have achieved with our technology in the medical monitoring field. Their results are set out in the 6 month Pilot Study Whitepaper by Dr. Olson titled "Biometric remote telemonitoring to produce a healthy return on investment, decrease resource utilization, and improve care coordination" is attached as Appendix A. Also available on request is our Cytta Technical Whitepaper summarizing the technical aspects of the Trial. Excerpts from Dr. Olson's Independent Report summarize the Cytta Technology Pilot Program as follows, "This trial demonstrated the ability to significantly reduce costs for high risk patients through use of the CYTTA Connect Ecosystem. The trial demonstrated the ability to quickly achieve cost savings, decrease resource utilization, improve care coordination, and increase adherence to evidence based guidelines." "Care costs were reduced on average by $11,078 for each trial participant through the trial [or $1,846 per member per month]. This trial did not specifically address long term cost of care. However, these patients were selected for the inabilities of the existing healthcare system and care coordination programs to cost effectively address their short or long term healthcare needs. One trial participant noted he realized more value and benefit in 2 months of trial participation compared to his previous 17 months of participation in the best available care coordination services."  "This trial discovered patients view CYTTA Connect and remote telemonitoring as a special benefit to patients who are encouraged to retain their relationship with Heritage to continue to access and build their personal health database. Patients develop a special relationship with their care coordination team. The patients viewed CYTTA Connect and care coordination activities as a value rather than an intrusion because information and advice generated by the trial were specific to the patient and time sensitive." "When compared to other remote telemonitoring services available, the CYTTA Connect Ecosystem is clearly the most cost effective, patient friendly system available." We have designed, built and completed a new technological product that will improve many lives and will vastly improve the way healthcare and any other data is transmitted and utilized. Accordingly, we have determined to be a facilitator of our services to anyone wishing to move data in a new and hitherto unavailable manner. We want to partner and will license any organization that can improve their model with our technology. Our objective is not to actively enter any specific marketplace, but to license our technology to partners, who have developed the considerable expertise necessary sell, deploy and operate in this sector and others. If you are offering any remote monitoring or data generating technology let us see how we can work together to improve the services you are offering.  Gary Campbell, President Contact: Mr. Gary Campbell, President Direct 702 900 7022 Office 702 253 7499 Website: Cytta.com info@cytta.com Appendix A Pilot Program Whitepaper Biometric remote telemonitoring to produce a healthy return on investment, decrease resource utilization, and improve care coordination By Terry Olson, MD  August 30, 2012 Background A large full risk, capitated medical group located in Southern California with employed and IPA physicians completed a six (6) month trial to determine if high cost patients not well managed in traditional care coordination programs and traditional healthcare delivery systems can decrease cost of care and improve patient satisfaction through remote telemonitoring using the CYTTA Connect Ecosystem and an intense case management process. Costs were realized in savings from: Hospital admissions Emergency Room Visits Urgent Care Visits Specialty Visits Methodology Twenty-seven (27) patients were identified through claims analysis with frequent use of primary care and specialty visits, Emergency Room visits, Urgent Care visits, Hospital admissions, two (2) or more co-morbidities, and little to no adherence to their current medical treatment plan. After further review, twenty (20) patients were enrolled in to this remote telemonitoring program trial. Resource utilization for the 180 days prior to enrollment in this pilot program was compared to monthly resource utilization during this trial. Patient and Provider satisfaction surveys were sent and interviews were completed with patients, care coordination staff, and physician providers who utilized the telemonitoring technology to determine their satisfaction with the program and case management. Recommendations were formulated at the completion of the trial.  This was a voluntary program which allowed patients to disenroll at any point during the trial. Patients who agreed to participate in the trial completed a 30 minute office orientation session to introduce the telemonitoring products and review the care coordination program. CYTTA provided technical resources, consultation to maintain device performance and all materials and services at no cost. All HIPPA requirements were incorporated into program design and care coordination processes.  Patients participated in the trial from their home after completing the orientation session. Technology performance issues were resolved remotely and within the patient's home for 4 patients. Biometric measurements were available for blood glucose, blood pressure, weight, and pulse oximetry. Results were sent via Bluetooth technology through double FDA approved off the shelf devices and transmitted to the CYTTA Connect dashboard. Access to the dashboard and ability to send care alerts were available to all members of the care coordination team, patients, and designated physicians/family members/caregivers.  Care coordination was provided by nurse and physician services through the existing complex case management employees. Alert programming was established by the Medical Director in association with discussions with primary care provider, specialty providers, and evidence based care guidelines. Alert prompts were sent to nurse care coordinators via email and texts. Nurse coordinators contacted patients in response to alert prompts and on a regular schedule during the trial. Face to face patient interaction with the care coordination team was not required but often transpired during the trial. Patients were able to participate remotely, through face to face interactions in the care coordination clinic, or through face to face home interactions.  Results Cost of care was reduced by $221,570 for the 20 patients in this 180 day trial. This equates to an average of $11,078 in cost reduction for each patient in the trial. Appendices 1-6 detail pre and post-trial costs of care and sites of utilization. Cost reductions were realized through reduced Emergency Room and Urgent Care visits, reduced specialty visits, and reduced hospital admissions. The reduction in hospital admissions was achieved largely through reduced readmissions. The table below summarizes utilization for trial members. The use of CYTTA Connect Ecosystem during this trial reduced utilization in the initial 90 days, but produced even more dramatic reductions in the second 90 day period. This supports the belief that patients began to learn how to better self-manage their conditions as they became familiar with the program and their care coordinators. The average reimbursement for a hospital inpatient DRG was estimated at $22,000; Emergency room visits average $1,200.00/visit; specialty physician visits average $125/visit while urgent care visits average $90/visit. Special note is made regarding 3 unavoidable hospital admissions with prolonged inpatient stays.  1. A member with no prior history of upper gastrointestinal bleeding developed abrupt hematemesis in addition to their diagnosis of end stage idiopathic pulmonary fibrosis. The member was admitted and spent 9 days in the hospital with a bleeding gastric ulcer.  2. A dialysis member with narcotic dependency, diabetes, and advanced degenerative spinal disease suffered a traumatic neck injury resulting in a 69 day stay and quadriplegia.  3. A member with idiopathic cardiomyopathy developed left ventricular assist device infection requiring hospital admission, LVAD removal, placement of an intra-aortic balloon pump and continued inpatient stay until a heart was found and heart transplantation completed. This resulted in a 73 day inpatient stay.  Summary of Trial results   Pre-trial Post-trial Last 90 days of trial Change Cost Savings Admits 28 17 3 9 $198,000 Readmits 12 5 0 7 $140,000 Bed Days 90 143 80 (53)   ER Visits 44 26 4 18 $21,600 UC Visits 12 4 1 8 $720 Specialists 102 92 36 10 $1,250 PCP 92 78 18 14 Capitated Total Cost Savings         $221,570 Cost Savings per Member over 6 months         $11,078 Cost savings per Member per month         $1,846 Value creation was identified in 4 areas during the trial: 1. Improved patient engagement and ability to self-manage care 2. Improved provider engagement 3. Patient loyalty 4. Improved care coordinating performance Enrollment criteria identified patients who struggled to manage their health despite best available resources in our current healthcare environment. This trial demonstrated these patients were not able to self-manage their care. The patients visited the hospital, emergency room, and physician offices in search of a solution to their healthcare needs. Those efforts were previously costly and ineffective.  Trial participation and the use of the CYTTA Connect Ecosystem discovered these patients were rarely engaged or knowledgeable in self-management of their healthcare needs. Repeated use of available resources did little to address this deficit. The CYTTA Connect Ecosystem in association with care coordination enabled the patient and team to identify and address barriers to self-management and adherence to evidence based guidelines. Barriers included knowledge deficits, outpatient monitoring deficits, absence of prompt and effective care plan revision when biometric guidelines were not met, and social factors.  Physician providers who participated in the trial voiced tremendous support for biometric remote telemonitoring. Physicians noted many of the previously reported home biometric monitoring was inaccurate, fabricated, or absent. Patients, physicians, and care coordination team members confirmed that biometric results were rapidly available and accurate. Sampling error or erroneous results reporting was not a problem. Physicians and care coordination team members noted their level of engagement and effectiveness was tremendously improved with accurate, timely, and frequent reports of blood pressure, blood sugar, weight, and oxygenation status.  As patients participated in the trial and received customized care coordination they became more engaged in their healthcare management and frequently voiced the admiration for effective service delivery. Patients commonly noted their neighbors, family members, church members, and others were amazed by the service delivered and wanted access to the trial. Patients noted they were not only more satisfied with the service delivered by the medical group but also noted they would never consider switching health plans or medical groups because they feared they would lose access to the CYTTA Connect Ecosystem and care coordination.  The complex care coordination team noted their ability to effectively manage and their personal satisfaction was tremendously increased through trial participation. The team noted the absence of playing telephone tag with patients and the absence of erroneous home biometric self-reports by patients. The team noted that the CYTTA Connect alerts required an active care plan which was clearly understood by the patient, the managing physicians, and the care coordination team. This was clearly absent prior to this trial. In addition, standing orders were required to promptly address care alerts so that blood pressure, blood sugars, weight, and oxygenation guidelines were met. The trial demonstrated the absence of effective, real time care plan and medication revision in existing care programs. The absence of timely care plan revision in addition to unclear care plans produced significant care team dissatisfaction. This trial and CYTTA Connect removed that dissatisfaction while improving care team performance.  Conclusions This trial demonstrated the ability to significantly reduce costs for high risk patients through use of the CYTTA Connect Ecosystem. The trial demonstrated the ability to quickly achieve cost savings, decrease resource utilization, improve care coordination, and increase adherence to evidence based guidelines. Adherence to evidence based guidelines is increasingly important as CMS 5 STAR ratings garner importance. Care costs were reduced on average by $11,078 for each trial participant. This trial did not specifically address long term cost of care. However, these patients were selected for the inabilities of the existing healthcare system and care coordination programs to cost effectively address their short or long term healthcare needs. One trial participant noted he realized more value and benefit in 2 months of trial participation compared to his previous 17 months of participation in the best available care coordination services. A quite handsome return on investment is present if the care coordination system is priced at less than $2,000 per year.  This trial also demonstrated that home biometric monitoring using the CYTTA Connect Ecosystem can be easily introduced, dispensed and utilized in the home setting. Care team training was easily completed. CYTTA Connect was easy for patients and care coordinators to learn and effectively use. Technical troubleshooting was prompt and effective.  Improved patient engagement and ability to self-manage care will become increasingly important and require new resource allocation because CMS will soon require Stage II Readiness participation. Through repeated collection and review of biometric data patients learn how to titrate medications and adjust behaviors to achieve target goals which is a cornerstone of CMS 5 STAR performance and CMS Stage II Readiness. Patients and the care coordination team are prompted by alerts to evaluate and to intervene in real time. This produces a patient who is more engaged and prospectively aware of how they must modify behaviors and medications to meet target metrics through self-management. Additionally, improved achievement of target metrics produces significant provider and care team satisfaction. Efforts of both become both more effective and more efficient.  Effective use of the CYTTA Connect Ecosystem requires the managing physicians to develop and communicate care plans and standing orders to adjust medications to achieve target goal. Too often the goals of care and associated care plans including medication administration are poorly communicated or not present. Patients travel through various sites of service and levels of care without a clear understanding of the expected behaviors and medication usage to be executed in the home setting. CYTTA Connect in conjunction with care coordination resolves this deficit and allows for care plan and medication revision as the patient disease processes change in the home environment. Through repeated measurement and with focused care coordination the patient learns how to better manage their health care needs. This produces a patient who is more engaged and prospectively aware of how they must modify behaviors and medications to meet target metrics. This also produces a more satisfied patient, physician, and care coordination team.  This trial discovered patients view CYTTA Connect and remote telemonitoring as a special benefit to patients who are encouraged to retain their relationship with Heritage to continue to access and build their personal health database. Patients develop a special relationship with their care coordination team. The patients viewed CYTTA Connect and care coordination activities as a value rather than an intrusion because information and advice generated by the trial were specific to the patient and time sensitive.  This trial enabled physicians and care coordinators to more effectively manage a larger number of patients. Current care coordination ratios can be expanded by 20% using biometric remote telemonitoring through reduced telephone tag and elimination of unfocused, subjective, generic discussions with patients. Instead specific biometric data, medication usage, review of the active care plan, and comparison to target metrics produces a focused discussion. Patients and care coordinators are taught through rapid cycle improvement to Plan, Do, Study, and ACT. Barriers to successful self-management are identified and addressed. Patients now learn how to revise and update their care management in the home setting rather than a physician office, emergency or hospital room followed by an attempt to translate and implement the care plan in their home setting upon discharge. Patient contacts have become value oriented with immediate return on investment to the care coordinators and patient.  Next Steps We believe the success of this remote telemonitoring program on managing high risk patients can be replicated and offered to forward thinking, at risk healthcare organizations. The telemonitoring success requires careful patient selection, structured patient enrollment and focused care coordination which have been developed and tested. Ongoing success requires structured patient assessment, patient and provider engagement, alert parameter selection with provider input with standing orders in response to alerts. CYTTA and MHIMS provides coordination between the providers and systems to introduce and educate on the use of the telemonitoring program to reduce ER and hospitalizations usage with increased patient involvement and increased positive outcomes in health self-management for high need members. We can identify high cost members and offer this program to non-high cost patients who are discharging from the hospital but at high risk for readmission due to their inability to effectively self-manage their care in the home setting.  When compared to other remote telemonitoring services available, the CYTTA Connect Ecosystem is clearly the most cost effective, patient friendly system available.  Although the pilot study was completed, CYTTA continued to provide their products which demonstrated additional cost savings and dramatically reduced utilization past the initial 180 day pilot. Contact: Mr. Gary Campbell President Direct 702 900 7022 Office 702 253 7499 Website: Cytta.cominfo@cytta.com

View More
Scroll down for more posts ▼

Top 10 Most Recent News Articles

SMPL Faces Legal Drama: What Investors Need to Know

Updated Category News Views 5

Investors Swim Against the Current With SMPL Picture this: You’re sipping your morning coffee, glancing through stocks, only to choke on your bagel when The Simply Good Foods Company (NASDAQ: SMPL) pops up with some less-than-palatable news. A class action is brewing, shouting out to investors who took the bait from October 24, 2024, to April 8, 2026. If you’re one of...

Continue Reading
U.S. Green Beret's Mission: Clearing Landmines in Ukraine

Updated Category News Views 3

The Rise of "Safe Ground" on Prime Video This isn't your typical feel-good story—it’s about grit and the unending fight for 'normalcy' where war left scars. Safe Ground, now streaming on Prime Video, showcases Ryan Hendrickson, a U.S. Army Green Beret whose story takes a sharp turn after stepping on an IED in 2010. The day he almost became just another statistic...

Continue Reading
OneOdio Showcases Innovation at IFA 2026 in Berlin

Updated Category News Views 5

Echoes from Berlin IFA 2026 in Berlin was a cacophony of innovation, as OneOdio wrapped up its showcase with a bang. Boasting interactive activities and live DJ sets, the event echoed OneOdio's drive to meld advanced audio technology with the pulsating needs of music pros and everyday listeners. You couldn’t miss the excitement in the air at Booth 217. Tech Unplugged:...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 1

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
D-Wave Faces Legal Questions After CFO Exit and Losses

Updated Category News Views 2

Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...

Continue Reading
Pizza: The Unlikely Symbol of Universal Togetherness

Updated Category News Views 6

Why Pizza Is More Than Just Food They say a slice of pizza can tell a story. Whether it's a late-night snack amongst college buddies or the centerpiece of a family's Friday tradition, pizza unites like few others can. It morphs from a study aid into a tool for togetherness without skipping a beat, much like a chameleon of the food world. And no one understands this better...

Continue Reading
New 2027 Jeep Wrangler JL-2A: A Blast from the Past

Updated Category News Views 5

Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 4

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 4

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Damp or Dry: The Battle for Healthy Air in Colorado

Updated Category News Views 5

The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...

Continue Reading

Top 5 Most Recently Viewed Articles

How to Read a Denver Monthly Market Report and Actually Use It to Your Advantage

Updated Category Real Estate Views 51

Most people who look at a Denver monthly market report do one of two things. They scan it quickly, feel vaguely informed, and move on without any clearer sense of what they should do. Or they look at a single number, usually the median price, decide the market is doing well or poorly based on whether that number went up or down, and make decisions on that basis. Neither...

Continue Reading
Exploring the Future of Night Vision Technology in Automotive Safety

Updated Category News Views 175

Overview of the Night Vision System Market The global night vision system market is witnessing remarkable growth. Recent forecasts point to an impressive expansion, with expectations to reach approximately USD 12,418.2 million by 2034, reflecting a compound annual growth rate (CAGR) of 13.1%. In particular, the market is projected to achieve USD 3,630.1 million by 2024,...

Continue Reading
The Joint Corp. Prepares for Q3 2025 Earnings Call Insights

Updated Category News Views 127

The Joint Corp. Prepares for Q3 Results SCOTTSDALE, Ariz. — The Joint Corp. (NASDAQ: JYNT), recognized as the leading provider of chiropractic care through its extensive The Joint Chiropractic network, is gearing up to announce its financial results for the third quarter of 2025. This significant update is expected to be released following the market close on a...

Continue Reading
Investigation into Dynavax Technologies and Shareholder Rights

Updated Category News Views 135

Investigation of Dynavax Technologies Corporation The Ademi Firm has initiated an investigation concerning Dynavax Technologies Corporation, a company traded on the Nasdaq under ticker DVAX. This probe focuses on potential breaches of fiduciary duty in light of Dynavax's recent agreement with Sanofi. The Deal Overview As part of this transaction, Dynavax shareholders are...

Continue Reading
Dana Incorporated Announces Quarterly Dividend Update

Updated Category News Views 41

Dana Incorporated Announces Quarterly Dividend Update Dana Incorporated (NYSE: DAN) has made an important announcement regarding its commitment to returning value to its shareholders. Today, the board of directors declared a quarterly dividend of $0.10 per share. This dividend is a testament to Dana's strong financial performance and its ongoing dedication to enhancing...

Continue Reading